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Aim: To assess outcomes among patients with Duchennemuscular dystrophy receiving deflazacort or pred-
nisone in real-world practice.Methods: Clinical data for 435 boys with Duchennemuscular dystrophy from
Cincinnati Children’s Hospital Medical Center were studied retrospectively using time-to-event and regres-
sion analyses. Results: Median ages at loss of ambulation were 15.6 and 13.5 years among deflazacort-
and prednisone-initiated patients, respectively. Deflazacort was also associated with a lower risk of scol-
iosis and better ambulatory function, greater % lean body mass, shorter stature and lower weight, after
adjusting for age and steroid duration. No differences were observed in whole body bone mineral density
or left ventricular ejection fraction. Conclusion: This single center study adds to the real-world evidence
associating deflazacort with improved clinical outcomes.
Lay abstract: This retrospective study described outcomes for boys with Duchenne muscular dystrophy
treated at Cincinnati Children’s Hospital Medical Center with the glucocorticoids deflazacort (∼95% daily
dosing) or prednisone (∼68% daily dosing). Patients receiving deflazacort had lower risk of losing am-
bulation, lost ambulation at older ages than those receiving prednisone, and had lower risk of scoliosis.
Across clinic visits, deflazacort was associated with greater preservation of ambulatory and pulmonary
function, shorter stature, lower bodyweight and greater % lean body mass. This study adds to the evi-
dence associating real-world dosing of deflazacort with improved outcomes for patients with Duchenne
muscular dystrophy.
First draft submitted: 13 November 2019; Accepted for publication: 16 December 2019; Published
online: 10 January 2020
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Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder characterized by progressive deterioration
in skeletal and cardiac muscles due to mutations in the dystrophin gene [1]. Globally, DMD affects approximately
one in every 3500 newborn males [2]. Initial manifestations of the disorder include progressive declines in ambulatory
function during childhood that typically culminate in complete loss of independent ambulation by adolescence [3].
Additional impacts include worsening cardiac and pulmonary function, as well as a deterioration in bone health;
over time, these disabling declines collectively contribute to mortality by early adulthood. The median survival for
boys with DMD is 21.8 years [4–8].
Corticosteroids are the current standard of care for patients with DMD, and have modified the natural history
of the disease by slowing the progression of motor and pulmonary functional decline and extending survival [9–11].
The beneficial effects of corticosteroids are attributed to their anti-inflammatory activity, particularly in muscles
with low levels of dystrophin, which can help preserve ambulation by delaying the loss of muscle strength [7,12]. The
glucocorticoids in use have been prednisone/prednisolone and deflazacort, an oxazoline derivative of prednisolone.
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Prolonged glucocorticoid steroid treatment is associated with linear growth failure, excessive weight gain and
heightened risk of osteoporosis [12,13].
Comparative studies of prednisone and deflazacort in DMD have been based on randomized trials [14–16], post-hoc
analyses of placebo-arm data [17,18] and on longer term analyses of natural history data [9–11]. While clinical trials
are the gold standard for assessing the efficacy and safety of therapeutics, data from electronic health records of
patients seen in clinics can be used to assess real-world outcomes. We aimed to study the outcomes associated
with deflazacort and prednisone/prednisolone treatments, including ambulatory, pulmonary, cardiac, growth and
bone-health outcomes, in patients with DMD with the use of real-world data from a large, single center cohort
receiving coordinated, collaborative and interdisciplinary patient- and family-centered care consistent with modern
guidelines for the management of DMD [19].
Patients
This is a retrospective cohort analysis of clinical data from electronic health records of patients with DMD who
attended the Comprehensive Neuromuscular Center at Cincinnati Children’s Hospital Medical Center (CCHMC)
from 2004 to March 2017. The de-identified data from an institutional review board (IRB) approved electronic clinic
registry (IRB #2010-1881) were curated for the following variables of interest: demographics, vitals, glucocorticoid
steroid use, bone density and body composition (via dual-energy x-ray absorptiometry [DEXA] scans), diagnosis of
scoliosis and measures of ambulatory, pulmonary and cardiac function. Patients included in the present study were
required to have a recorded date of steroid initiation and a recorded steroid type in the CCHMC database. The
majority (99%) of clinic visits and follow-up time included in this study occurred prior to the US FDA approval of
deflazacort in February 2017; during this period patients took imported deflazacort. The outcomes of interest were
ages at clinical events (loss of ambulation and scoliosis); patients’ ambulatory, pulmonary and cardiac function; and
weight, lean body mass and bone health.
Statistical methods
Analyses of ages at clinical events
For the analyses of ages at clinical events, included patients were categorized into prednisone- and deflazacort-
initiated groups based on their first recorded steroid type. Patient characteristics during the first clinic visit and
their dosing regimens (daily vs other) were summarized in these groups. Means and standard deviations (SD) were
reported for continuous characteristics; counts and percentages were reported for categorical characteristics.
Loss of ambulation was identified as Functional Mobility Scale (FMS) score >4, which is indicative of patients’
full-time use of a wheelchair for mobility in DMD. The FMS ranges from 1 (mild gait abnormalities) to 8 (unable
to sit without support) with FMS 1–4 for ambulatory patients and 5–8 for nonambulatory patients. Patients
studied for this outcome were required to have an FMS score of 1–4 at their first clinic visit.
Age at onset of scoliosis was defined as the first recorded clinical diagnosis of scoliosis in the patient’s medical
record. Clinical diagnosis of scoliosis at CCHMC is determined based on clinical examination and confirmation
with spine radiographic reports finding Cobb’s angle >20 degrees. Patients studied for time to scoliosis were
required to be free of scoliosis at their first clinic visit.
Age at first occurrence of FMS >4 and first diagnosis of scoliosis were studied in time-to-event analyses, with
age as the time variable, and censoring at the end of data availability. Kaplan-Meier curves and log-rank tests were
calculated to compare these outcomes between steroid initiation groups. Cox proportional hazards analyses were
used to estimate the association between steroid type and age at event while adjusting for age at steroid initiation, the
calendar year during which the patient had initiated steroid use, and whether the patient had initiated steroids prior
to or after their first clinic visit at CCHMC. The adjusted analyses thus accounted for differences in the duration of
steroid exposure, potential temporal trends that might impact outcomes across groups, and potential differences in
care received prior to CCHMC. Sensitivity analyses were conducted distinguishing between patients who received
daily versus other regimens of prednisone and, separately, distinguishing those who maintained prednisone versus
those who switched to deflazacort after initiation.
Analyses of average outcomes across clinic visits
For the analyses of associations between steroid type and clinical status, patients’ clinic visits were included in
the analysis if the patient was ≥4 years of age at the visit and consistently used either prednisone or deflazacort
while under care at CCHMC. Patients who switched steroids were excluded from this analysis, as the precise
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date of switching was not always available. Studied outcomes included: functional outcomes (4 stair climb [4SC]
velocity [stairs/second]; 30-ft walk/run velocity [feet/seconds]; timed sit-to-stand velocity [1/seconds]; North Star
Ambulatory Assessment [NSAA] total score), forced vital capacity (FVC) %-predicted; left ventricular ejection
fraction (LVEF) %; body size and composition (height [cm], total body mass [kg], % lean body mass, % body
fat); and bone health assessed as whole body bone mineral density (BMD in g/cm2) using DEXA. Analyses of
each outcome included only those visits at which the outcome was measured. For ambulatory function tests, this
excluded visits at which the test was not conducted because the patient was not willing or able to complete the test.
Multivariable regression analyses were used to estimate cross-sectional associations between steroid type (de-
flazacort or prednisone) and each outcome measure across all assessments. These analyses estimated the average
differences observed during clinic visits between patients receiving deflazacort and those receiving prednisone. The
analyses were adjusted for current age, years since steroid initiation, whether the patient had begun taking steroids
prior to or after their first clinic visit at CCHMC, and current visit year, as well as the interaction between current
age and years since steroid initiation. The inclusion of the interaction term allows the effect of duration of steroid
exposure to potentially vary by current age. Adjustment for visit year (i.e., the calendar year of the visit) accounts
for potential temporal factors that might have influenced outcomes. Adjusting for whether the patient had initiated
steroids prior to or after their first clinic visit at CCHMC accounts for potential differences in care received prior
to CCHMC. Generalized estimating equations with an exchangeable correlation structure were used to account
for the use of multiple clinic visits per patient.
Results
Patient characteristics
Among n = 600 total boys in the CCHMC database, n = 559 had their date of steroid initiation recorded and
n = 500 had a steroid type recorded at some point during their follow-up history at CCHMC. A further n = 435 of
these patients had at least one assessment of FMS or an assessment for scoliosis. Among these patients, at their first
clinic visit at CCHMC, those treated with prednisone (n = 105; 68% daily) had a mean (±SD) age of 8.1 (±3.1)
years, while patients treated with deflazacort (n = 330; 95% daily) had a mean age of 6.5 (±3.1) years (Table 1). A
little over half of the patients had initiated steroids prior to their first clinic visit at CCHMC, and the proportion
doing so differed by steroid type (75% for prednisone and 48% for deflazacort); for these patients the average time
between steroid initiation and first clinic visit was similar between steroid groups at 2.5 and 2.3 years, respectively.
The overall average follow-up included in the time-to-event analyses was 11.2 years in the FMS analyses and
11.9 years in the scoliosis analyses. The follow-up time was similar across prednisone- and deflazacort-initiated
patients (<6 months difference in mean follow-up time).
At first clinic visit at CCHMC with functional data recorded, deflazacort-initiated patients were on aver-
age younger, shorter and weighed less, compared with prednisone-initiated patients (Table 1). The deflazacort-
initiated group was also younger on average at steroid initiation compared with the prednisone-initiated group (5.7
vs 6.4 years, respectively). Across measures of ambulatory, pulmonary and cardiac function at the first clinic visit at
CCHMC, deflazacort-treated patients tended to have better or similar function compared with prednisone-treated
patients.
Analyses of ages at clinical events
During follow-up at CCHMC, 107 patients lost ambulation (FMS >4; deflazacort-initiated patients: 22.9%
[73/319]; prednisone–initiated patients: 35.8% [34/95]) (Figure 1). Loss of ambulation occurred at significantly
older ages for deflazacort-initiated patients; the median age at transition was 15.6 years in the deflazacort-initiated
group and 13.5 years in the prednisone-initiated group (log-rank p < 0.01). By age 15 years, 56% of prednisone-
initiated patients had lost ambulation, compared with 43.7% of deflazacort-initiated patients.
During follow-up at CCHMC, 42 patients developed scoliosis (deflazacort-initiated patients: 7.9% [25/317];
prednisone-initiated patients: 17.9% [17/95]) (Figure 2). Scoliosis occurred at significantly older ages for patients
initiating deflazacort compared with prednisone; the median age was not reached in the deflazacort-initiated
group, whereas the median age of scoliosis onset was 18.6 years in the prednisone-initiated group (log-rank test
p = 0.05). Based on the Kaplan–Meier estimates, by age 15 years, 13.7% of prednisone-initiated patients and 8.9%
of deflazacort-initiated patients had scoliosis.
These associations persisted in Cox proportional hazards analyses that adjusted for age at steroid initiation, year
of steroid initiation and whether the patient had initiated steroids prior to or after their first clinic visit at CCHMC
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Table 1. Patient characteristics by first recorded steroid type†.
PRED (N = 105) DFZ (N = 330)
Demographics and body size/composition
Age at first clinic visit at CCHMC (years): 8.1 ± 3.1 6.5 ± 3.1
– Median (IQR) 7.9 (5.8–9.7) 6.0 (4.5–8.0)
– Range 0.3 – 19.5 0.2 – 25.3
Age at first clinic visit at CCHMC with FMS (years) 8.7 ± 3.3 7.1 ± 3.4
Height (cm) 125.4 ± 17.1 113.2 ± 15.4
Weight (kg) 33.0 ± 16.2 24.2 ± 11.1
BMI (kg/m2) 19.7 ± 4.5 18.1 ± 3.8
% lean body mass (DEXA) 64.1 ± 10.3 70.0 ± 9.0
Steroid use
Age at steroid initiation (years) 6.4 ± 2.5 5.7 ± 2.1
Initiation prior to first clinic visit at CCHMC, n (%): 79 (75.2) 157 (47.6)
– Years from initiation to first clinic visit at CCHMC 2.5 ± 2.3 2.3 ± 2.4
Dosing frequency at first recorded steroid, n (%):‡
– Daily 69 (67.7%) 310 (95.1%)
– Other 33 (32.4%) 16 (4.9%)
Switched steroid type during follow-up at CCHMC, n (%):
– Deflazacort → prednisone – 14 (4.2%)
– Prednisone → deflazacort 44 (41.9%) –
Calendar year of steroid initiation:
– 1993–2000 0 (0.0%) 7 (2.1%)
– 2000–2008 42 (40.0%) 142 (43.0%)
– 2009–2016 63 (60.0%) 181 (54.9%)
Ambulatory function
NSAA total score 17.8 ± 6.8 20.7 ± 6.4
FMS 2.5 ± 1.3 1.9 ± 1.0
Timed sit-to-stand (s) 4.7 ± 4.1 2.8 ± 2.0
Timed 30-ft walk/run (s) 5.8 ± 2.2 5.2 ± 2.1
Timed 4-stair climb (s) 3.6 ± 2.0 3.7 ± 2.8
Pulmonary and cardiac function
FVC (l) 2.1 ± 0.4 1.7 ± 0.5
FVC %-predicted 95.3 ± 21.8 99.6 ± 25.1
LVEF % 58.6 ± 7.7 61.2 ± 8.7
†Patient characteristics are summarized at the time of the first clinic visit at CCHMC with either an FMS or scoliosis assessment recorded unless otherwise noted. Statistics
reported are means ± standard deviations unless otherwise noted.
‡Percentages calculated among the n = 102 and n = 326 patients with nonmissing dosing data for prednisone and deflazacort groups, respectively.
BMI: Body mass index; CCHMC: Cincinnati Children’s Hospital Medical Center; DEXA: Dual-energy x-ray absorptiometry; DFZ: Deflazacort; FMS: Functional mobility scale; FVC:
Forced vital capacity; IQR: Interquartile range; LVEF: Left ventricular ejection fraction; NSAA: North Star Ambulatory Assessment; PRED: Prednisone; SD: Standard deviation.
(Table 3). Relative to treatment with prednisone, treatment with deflazacort was associated with a reduction in
the hazard of loss of ambulation by 53% and with a reduction in the hazard of scoliosis by 59%. Hazard ratios
were similar in both the adjusted and unadjusted analyses. The age at loss of ambulation findings were robust to a
sensitivity analysis that excluded the n = 11 patients who required orthotics or braces to walk at their first assessment
(i.e., FMS = 4).
In sensitivity analyses with dosing frequency data available, comparisons between deflazacort (95% daily) and
separated groups receiving daily versus other regimens of prednisone yielded findings consistent with those of the
main analyses for ages at loss of ambulation and scoliosis (Supplementary Table 1).
In the separate sensitivity analyses among patients with switching data available, there were n = 44 patients
initiated on prednisone who switched to deflazacort (42% out of 105) and n = 14 who initiated on deflazacort
and switched to prednisone (4.2% out of 330). Among the subset of switchers from prednisone to deflazacort
with duration data available (about 28% of the n = 44), the average duration on prednisone was 3.1 years and
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Figure 1. Age at loss of ambulation (functional mobility scale >4) by first recorded steroid type (Kaplan–Meier
analysis).
FMS: Functional Mobility Scale.
the average subsequent duration on deflazacort was 2.5 years. Times to scoliosis and loss of ambulation among
prednisone-to-deflazacort switchers were numerically prolonged compared with patients continuing on prednisone,
but shorter compared with patients initiated with deflazacort (Supplementary Table 2). Initiation with deflazacort
was associated with a reduction in the hazard of loss of ambulation by 64% relative to being treated with prednisone
only. Switching from prednisone to deflazacort was numerically associated with a reduction in the hazard of loss
of ambulation by 51% relative to being treated with prednisone only. Similarly, initiation with deflazacort was
associated with a reduction in the hazard of incurring the onset of scoliosis by 61%, and switching from prednisone
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Figure 2. Age at scoliosis diagnosis by first recorded steroid type (Kaplan–Meier analyses).
to deflazacort was numerically associated with a reduction in the hazard of incurring scoliosis by 13%, relative to
being treated with prednisone only.
Analyses of average outcomes across clinic visits
When analyzing associations between steroid type and outcomes across all clinic visits, the sample sizes varied
according to the assessment frequency of each outcome as follows: 4SC velocity: 1519 total observations from
285 patients; 30-ft walk/run velocity: 1794 observations from 303 patients; timed sit-to-stand velocity: 1651
observations from 294 patients; NSAA: 1400 total observations from 294 patients; FVC %-predicted: 1193 total
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Table 2. Cross-sectional associations between steroid type and patient status.
Outcome
† ,‡ Difference between DFZ
(N = 330) vs PRED
(reference group; N = 105)
95% CI p-value
4SC (velocity) (stairs/seconds)
Unadjusted 0.54 (0.31–0.78) 0.001§
Adjusted 0.63 (0.37–0.88) 0.001§
30-ft walk/run (velocity) (feet/seconds)
Unadjusted 1.16 (0.66–1.67) 0.001§
Adjusted 1.35 (0.82–1.87) 0.001§
Timed sit-to-stand (velocity) (1/seconds)
Unadjusted 0.13 (0.08–0.18) 0.001§
Adjusted 0.13 (0.08–0.17) 0.001§
NSAA (total score)
Unadjusted 4.22 (2.23–6.22) 0.001§
Adjusted 4.65 (2.63–6.68) 0.001§
FVC %-predicted (%)
Unadjusted 14.74 (7.55–21.92) 0.001§
Adjusted 9.24 (3.06–15.41) 0.01§
LVEF (%)
Unadjusted 1.69 (-0.86–4.24) 0.19
Adjusted 0.87 (-1.58–3.32) 0.49
Height (cm)
Unadjusted -12.84 (-18.18 to -7.50) 0.001§
Adjusted -5.96 (-8.41 to -3.51) 0.001§
Total body mass (kg)
Unadjusted -12.31 (-17.14 to -7.47) 0.001§
Adjusted -6.67 (-10.21 to -3.13) 0.001§
% Lean body mass (%)
Unadjusted 7.22 (4.57–9.87) 0.001§
Adjusted 4.52 (2.41–6.64) 0.001§
% Body fat (%)
Unadjusted -7.56 (-10.37 to -4.75) 0.001§
Adjusted -4.73 (-6.97 to -2.50) 0.001§
Whole body BMD (g/cm2)
Unadjusted -0.03 (-0.05 to -0.01) 0.001§
Adjusted -0.00 (-0.02–0.01) 0.76
†Multivariable regressions adjusted for age at visit, visit year, steroid duration, an interaction term between age and steroid duration, and initiation of steroids prior to first
clinic visit at Cincinnati Children’s Hospital Medical Center.
‡For both the unadjusted and adjusted analyses, the reported values reflect the results for deflazacort versus prednisone (reference group) on the outcome of interest. Patients
who switched steroids were not included in this analysis.
§Denotes statistical significance.
4SC: 4-Stair climb; BMD: Bone mineral density; DFZ: Deflazacort; FVC: Forced vital capacity; LVEF: Left ventricular ejection fraction; NSAA: North Star Ambulatory Assessment;
PRED: Prednisone.
observations from 256 patients; LVEF %: 687 total observations from 225 patients; total body mass: 1886 total
observations from 314 patients; height: 2237 total observations from 326 patients; % lean body mass and % body
fat: 1886 total observations from 314 patients; and whole body BMD: 1886 total observations from 314 patients.
On average, patients had clinical visits spanning 4.9 years, with a mean of seven visits per patient. Across all visits
used in cross-sectional analyses, patients had a median age of 9.9 years (interquartile range: 7.4–12.9 years). The
median age across all visits was higher in the prednisone group (11.3 years) compared with the deflazacort group
(9.6 years).
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Table 3. Cox proportional hazards analyses for time to loss of ambulation and scoliosis.
Outcome
† ,‡ Hazard ratio for DFZ (N = 330) vs PRED
(N = 105)
95% CI p-value
Loss of ambulation (FMS >4)
Unadjusted 0.55 (0.36–0.83) 0.01§
Adjusted 0.47 (0.30–0.74) 0.01§
Scoliosis onset
Unadjusted 0.54 (0.29–1.01) 0.05
Adjusted 0.41 (0.21–0.82) 0.05§
†Adjusted for age at steroid initiation, year at steroid initiation and whether the patient had initiated steroids prior to or after their first clinic visit at Cincinnati Children’s Hospital Medical
Center.
‡For both the unadjusted and adjusted analyses, the reported values reflect the results for deflazacort versus prednisone (reference group) on the outcome of interest.
§Denotes statistical significance.
DFZ: Deflazacort; FMS: Functional Mobility Scale; PRED: Prednisone.
Cross-sectional analyses
Cross-sectional associations between steroid type and patient status across all clinic visits (unadjusted and adjusted)
are summarized in Table 2. After adjusting for age at the clinic visit, steroid duration as of the visit, the calendar
year of the visit, and whether the patient had initiated steroids prior to or after their first clinic visit at CCHMC
in a regression analysis as well as the interaction between age at clinic visit and steroid duration, patients treated
with deflazacort, on average, exhibited a significantly greater 4SC velocity compared with patients treated with
prednisone (by 0.63 stairs/s) across all clinic visits at which this assessment was conducted (p < 0.001). On average
in these adjusted analyses, across all clinic visits with assessments recorded, patients treated with deflazacort also
had a greater 30-ft walk/run velocity (by 1.35 feet/s), a greater timed sit-to-stand velocity (by 0.13 1/s), a higher
NSAA total score (by 4.7 points), a higher FVC %-predicted (by 9.2 percentage points), a higher % lean body
mass (by 4.5 percentage points) and a lower % body fat (by 4.7 percentage points) compared with patients treated
with prednisone (all p < 0.05). Patients treated with deflazacort also had a lower mean total body mass (by 6.7 kg)
and were shorter on average (by 6.0 cm) compared with patients treated with prednisone (all p < 0.05). Similar
results were observed when regression analyses for height and FVC %-predicted were additionally adjusted for the
type of height assessment (e.g., standing, wingspan, segmental measurements). No significant differences between
steroid types were observed across assessments for LVEF % or whole body BMD.
Discussion
This retrospective analysis of real-world data from a single, large DMD care center identified associations between
the use of deflazacort and greater preservation of ambulatory and pulmonary function, and prolonged time to loss
of ambulation and scoliosis, compared with the use of prednisone. Deflazacort was also associated with shorter
stature, lower total bodyweight and greater % lean body mass.
Loss of ambulation represents a clinically meaningful milestone in DMD progression [9,11,20]. The results of
the present study align with prior evidence associating deflazacort with delayed loss of ambulation [9,20–22]. For
example, in a 2006 study conducted among 74 boys (ages 10–18 years) with DMD, patients treated with deflazacort
(mean treatment duration 5.5 years) were able to rise from supine to standing, climb stairs and walk 10 meters
without assistance for 3–5 years longer than those in a placebo group [22]. A 2015 study utilizing the Cooperative
International Neuromuscular Research Group (CINRG) natural history database also associated deflazacort with
delayed loss of ambulation; participants who received deflazacort treatment for ≥1 year had a median 3-year
longer delay in loss of ambulation compared with those receiving prednisone (p < 0.001) [9]. Similarly, results of
a 2018 study utilizing the CINRG database found that long-term treatment with deflazacort was associated with
an increase in the median ages at the loss of ambulation by approximately 2 years compared with patients treated
with prednisone [20]. Our finding of a near similar 2-year delay in the time to loss of ambulation with deflazacort
compared with prednisone treatment in a single large care center, with homogenous care recommendations across
patients, supports the prior finding, based on a global multi-center study, of a better motor outcome with deflazacort
treatment compared with prednisone/prednisolone treatment.
Scoliosis is an important comorbidity of DMD that is closely associated with muscle weakness and loss of
ambulation [23–25]. The consequences of scoliosis are significant, and complications associated with surgery to
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correct spinal deformities can further exacerbate the disease burden in DMD [23]. The lower risk of scoliosis observed
among patients receiving deflazacort compared with prednisone in the current study is clinically meaningful, and
concordant with the greater preservation of ambulatory function observed among the deflazacort-treated patients.
While there were only a small number of patients switching from prednisone to deflazacort in the present study,
this group exhibited hazards of loss of ambulation and scoliosis that were numerically intermediate relative to
patients who consistently received prednisone (highest risk) and those who initiated deflazacort (lowest risk).
In addition to studying ages at clinical events, our study assessed differences between deflazacort- and prednisone-
treated patients across all clinic visits. Differences in ambulatory function across visits reached magnitudes deemed
clinically meaningful in prior research [26–28]. For example, a previous study reported that a difference of 2–4
points in the NSAA total score and a difference of 0.3–0.6 stairs/s in 4SC velocity represent clinically meaningful
differences [28]. Across clinic visits, the present study found numerically higher performance on NSAA (by 4.6 points)
and 4SC velocity (by 0.59 stairs/s) associated with deflazacort compared with prednisone use, after accounting for
the patient’s age and duration of steroid treatment at the clinic visit.
The lower weight and shorter height among patients treated with deflazacort versus prednisone in the present
study replicate well-known associations for these treatments [14,29,30]. Underlying these changes in overall body
size, deflazacort was associated with a more favorable body composition compared with prednisone in the present
study, with higher % lean body mass and lower % body fat. As lean mass largely reflects muscle mass [31], the higher
levels of % lean body mass observed among patients using deflazacort versus prednisone align with the observed
differences in ambulatory function between the two treatment groups.
This study found no evidence of a difference in whole body BMD between deflazacort- and prednisone-treated
patients. This was surprising given that a previous study has associated daily deflazacort with an annualized fracture
risk of 1367 per 10,000 person years, an almost twofold higher risk compared with daily prednisone [32]. Fracture
data were not available for the current study, and further investigation of this outcome is needed. Other adverse
effects of steroids that were not available in the present database but warrant further study include Cushingoid
appearance, insulin resistance and behavioral changes.
Declines in respiratory function due to progressive muscle weakening are a significant contributor to the
morbidity and mortality in DMD [33]. Patients receiving deflazacort in the present study had, on average, better
pulmonary function with higher FVC %-predicted compared with patients receiving prednisone. The higher %-
predicted values for deflazacort-treated patients versus prednisone/prednisolone-treated patients may be related to
the shorter stature of deflazacort-treated patients since height is the denominator for calculating FVC %-predicted
FVC. Greater preservation of pulmonary function with deflazacort was also observed in the aforementioned 2018
study utilizing the CINRG database, which estimated a delay in median age at FVC <1L by approximately 2 years
compared with treatment with prednisone [20].
Cardiac disease is the primary cause of mortality in over 20% of patients with DMD due to the dystrophin gene
defect causing an absence of the muscle cytoskeletal protein dystrophin and leading to cardiac muscle disease [34–36].
This study found no evidence of a difference in LVEF % between patients treated with deflazacort or prednisone.
Patients in both the deflazacort and prednisone groups had an average LVEF % of over 55% (59 and 58%,
respectively), indicating that LVEF % was preserved during the majority of follow-up.
Limitations
The principal limitation of this study is that steroid use was not randomized as in a clinical trial. Therefore,
differences in outcomes between steroid groups could be confounded by factors that differ between these groups.
Some of these factors could be accounted for in our analyses via regression adjustment. For example, the younger
average age at steroid initiation for deflazacort-treated patients could impact outcomes, but was accounted for by
adjusting for age at steroid initiation. It could also be hypothesized that differences in care received prior to CCHMC,
including potential differences in steroid dosing or supportive care, could have impacted outcomes. Indeed, a higher
proportion of patients initiating prednisone did so prior to CCHMC compared with those initiating deflazacort.
For this reason, our analyses adjusted for whether or not steroids were initiated prior to the first clinic visit at
CCHMC, among other factors. However, despite these adjustments for observed differences between groups, it is
possible that unobserved differences are present. In particular, it was not possible to identify the extent to which
potential differences in socioeconomic status (SES) may have affected the results. Cost has been a factor for most
families at CCHMC who opt for prednisone instead of out-of-pocket, imported deflazacort. Prednisone is also
cheaper in other countries. Generally, families at CCHMC with higher SES tend to have better adherence to care
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plans. For example, care plans may include recommendations for self- or family-administered physiotherapy such
as stretching, night brace usage and nutritional/weight management; adherence to these recommendations could
be impacted by SES through differences in self-efficacy, social support, or anxiety/depression [37,38].
The impact of different dosing regimens is a plausible contributor to the differences in outcomes observed in the
present study between patients receiving prednisone and deflazacort. In particular, the impact of excessive weight
gain with prednisone/prednisolone [14] could have resulted in lower tolerated doses of prednisone/prednisolone as
in the CINRG cohort (cumulative dose of daily prednisone patients was 1729 mg or equivalent deflazacort dose of
2075 mg vs cumulative dose of 2922 mg) [20]. In this way, differences in functional outcomes and scoliosis risk could
be explained by better tolerability of deflazacort to enable more optimal dosing of recommended 0.9 mg/kg/day
as opposed to a lower dose of prednisone due to its side effect of excessive weight gain. Indeed, a randomized trial
of fixed daily doses of prednisone (0.75 mg/kg/day) and deflazacort (0.9 mg/kg/day) identified no significant
differences in motor function, but substantially greater weight gain with prednisone [14]. While sensitivity analyses
separating out daily and other regimens of prednisone identified results consistent with those of the main analyses,
our study is limited by the lack of data on cumulative or time-varying doses of deflazacort and prednisone. It was
not possible to compare dose-adjusted outcomes. Rather, the outcomes observed in the present study represent
those associated with real-world, individualized dosing for each steroid type at CCHMC. Beyond differences in
dosing, other potential differences between deflazacort and prednisone, including greater reduction of interferon
gamma levels [39] and potential immunomodulatory effects [39–42], or lower protein binding and nonaffinity for
transcortin and potential impacts on bioavailability in muscle fibers [43–46], could be speculated to impact functional
outcomes, but were not investigated in the present study.
As a study of real-world data captured in clinical practice, there are also limitations stemming from the data col-
lection process. In particular, ambulatory test results were not available from patients who were unable or unwilling
to complete the assessments. Thus, the cross-sectional analyses of ambulatory function represent differences among
patients who completed those tests.
Conclusion
This study of real-world data adds to the evidence from other observational studies associating the use of deflazacort
with greater preservation of motor and pulmonary function relative to the use of prednisone, and further indicates
concurrent preservation of lean body mass and delay of scoliosis.
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Summary points
• The corticosteroids prednisone and deflazacort represent the standard of care in Duchenne muscular dystrophy
(DMD), and real-world evidence is needed to fully characterize their effectiveness.
• This retrospective cohort study analyzed clinical outcomes (ambulatory, pulmonary, cardiac, bone-health) of
435 patients with DMD from Cincinnati Children’s Hospital Medical Center who received deflazacort only (∼95%
daily regimen), prednisone only (∼68% daily regimen), or were switched from prednisone to deflazacort.
• Treatment with deflazacort was associated with a significant delay in loss of ambulation relative to treatment
with prednisone (15.6 vs 13.5 years).
• The onset of scoliosis was significantly delayed among patients treated with deflazacort (median age of onset not
reached) versus prednisone (median age of onset: 18.6 years).
• On average across clinic visits, and after accounting for current age, duration of steroid treatment, whether the
patient had initiated steroids prior to or after their first CCHMC clinic visit, and current visit year,
deflazacort-treated patients experienced significantly greater 4-stair climb velocity, 30-ft walk/run velocity, timed
sit-to-stand velocity, greater North Star Ambulatory Assessment total score, greater forced vital capacity
%-predicted, greater % lean body mass and a greater % body fat compared with patients treated with
prednisone. Patients treated with deflazacort also had a lower mean total body mass and were shorter, on
average, compared with patients treated with prednisone.
• No significant differences in whole body bone mineral density or left ventricular ejection fraction were observed
among treatment groups.
• Patients who switched from prednisone to deflazacort experienced a numerically greater delay in their loss of
function compared with patients treated with prednisone only, but less of a delay compared with those who
were treated with deflazacort.
• Overall these findings suggest that, with real-world steroid dosing, slower functional decline is associated with
deflazacort treatment compared with prednisone. Studies with randomized steroid assignment are necessary to
assess treatment effects without confounding by socioeconomic status or other factors, and to identify and
compare optimal dosing.
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